Liquidia (LQDA) Non Operating Interest Expenses (2020 - 2026)
Liquidia (LQDA) posted Non Operating Interest Expenses of $6.3 million for Q2 2026, down 3.05% on a QoQ basis from $6.5 million in Q1 2026, and up 11.28% year-over-year from $5.7 million in Q2 2025.
Analysis
Liquidia (LQDA) Non Operating Interest Expenses (2020 - 2026) Analysis & Trends
Liquidia has reported Non Operating Interest Expenses for 7 years, with the latest figure at $6.3 million in Q2 2026.
- On a quarterly basis, Non Operating Interest Expenses rose 11.28% year-over-year to $6.3 million in Q2 2026; TTM through Jun 2026 was $26.6 million, a 44.04% increase from a year earlier, with the FY2025 full-year figure at $24.2 million, up 64.99% from the prior year.
- Non Operating Interest Expenses was $6.3 million for Q2 2026 at Liquidia, down from $6.5 million in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $6.9 million in Q3 2025, with the low at $478000.0 in Q1 2022.
- Average Non Operating Interest Expenses over 5 years is $3.3 million, with a median of $3.2 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2026: Non Operating Interest Expenses jumped 242.16% in 2022, then advanced 11.28% in 2026.
- Over 5 years, Non Operating Interest Expenses stood at $698000.0 in 2022, then jumped by 181.09% to $2.0 million in 2023, then surged by 129.71% to $4.5 million in 2024, then surged by 53.07% to $6.9 million in 2025, then declined by 8.74% to $6.3 million in 2026.
- The last three Non Operating Interest Expenses figures came in at $6.3 million (Q2 2026), $6.5 million (Q1 2026), and $6.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.62 Bn | 625.86 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 442.20 Bn | 435.63 Bn | 12.70 Bn | - |
| 3 | Merck | 366.42 Bn | 359.28 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.80 Bn | 259.11 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 159.12 Bn | 147.42 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 23.78 Mn |
| 8 | Incyte | 25.39 Bn | 20.85 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.45 Bn | 18.78 Bn | 683.80 Mn | 2.90 Mn |
| 10 | Liquidia | 6.07 Bn | 5.79 Bn | 160.92 Mn | 6.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.30 Mn |
| Mar 31, 2026 | 6.49 Mn |
| Dec 31, 2025 | 6.90 Mn |
| Sep 30, 2025 | 6.95 Mn |
| Jun 30, 2025 | 5.66 Mn |
| Mar 31, 2025 | 4.67 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Sep 30, 2024 | 3.66 Mn |
| Jun 30, 2024 | 3.33 Mn |
| Mar 31, 2024 | 3.16 Mn |
| Dec 31, 2023 | 1.96 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 1.43 Mn |
| Mar 31, 2023 | 1.12 Mn |
| Dec 31, 2022 | 698,000.00 |
| Sep 30, 2022 | 620,000.00 |
| Jun 30, 2022 | 542,000.00 |
| Mar 31, 2022 | 478,000.00 |
| Dec 31, 2021 | 204,000.00 |
| Sep 30, 2021 | 205,000.00 |